Post-Interleukin 6
| Zeile 25: | Zeile 25: | ||
{{tp|p=32278585|t=2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab |pdf=|usr=}} | {{tp|p=32278585|t=2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab |pdf=|usr=}} | ||
{{tp|p=32352361|t=2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists |pdf=|usr=}} | {{tp|p=32352361|t=2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists |pdf=|usr=}} | ||
| − | + | {{tp|p=32253759|t=2020. Tocilizumab treatment in COVID-19: A single center experience |pdf=|usr=}} | |
{{tp|p=32171193|t=2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies |pdf=|usr=}} | {{tp|p=32171193|t=2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies |pdf=|usr=}} | ||
| − | + | {{tp|p=32209313|t=2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws |pdf=|usr=}} | |
| − | + | {{tp|p=32369191|t=2020. Tocilizumab for the treatment of severe coronavirus disease 2019 |pdf=|usr=}} | |
| − | + | {{tp|p=32297987|t=2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection |pdf=|usr=}} | |
{{tp|p=32358817|t=2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome |pdf=|usr=}} | {{tp|p=32358817|t=2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome |pdf=|usr=}} | ||
{{tp|p=32282956|t=2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab |pdf=|usr=}} | {{tp|p=32282956|t=2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab |pdf=|usr=}} | ||
| + | {{tp|p=C7187784|t=ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab |pdf=|usr=}} | ||
| + | {{tp|p=32350134|t=2020. Effective treatment of severe COVID-19 patients with tocilizumab |pdf=|usr=}} | ||
| + | {{tp|p=32365207|t=ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report |pdf=|usr=}} | ||
| + | {{tp|p=32376396|t=2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?|pdf=|usr=}} | ||
| + | {{tp|p=32380318|t=2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |pdf=|usr=}} | ||
| + | {{tp|p=32402416|t=ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides ... |pdf=|usr=}} | ||
| + | {{ttp|p=32321563|t=2020. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome |pdf=|usr=}} | ||
| + | {{tp|p=32389721|t=ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation |pdf=|usr=}} | ||
| + | {{tp|p=C7154570|t=2020. Anti-IL6R role in treatment of COVID-19-related ARDS |pdf=|usr=}} | ||
| + | |||
| + | {{tp|p=32387320|t=ä. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 13:55 Uhr
32353761 2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
32247642 ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
32243501 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
32343968 ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
32337664 ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
32359035 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
32378647 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
32234467 ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
32305588 ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
32291137 ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
32300051 2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32290839 2020. Why tocilizumab could be an effective treatment for severe COVID-19?
32372149 ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
32367812 2020. Fyrsta meethfereth meeth tocilizumab vieth COVID-19 herlendis - sjukratilfelli
32327746 ä. Translating IL-6 biology into effective treatments
32325121 ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19
32380318 ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32359210 2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report
32324331 2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine
32376396 ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32376398 ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
32299796 2020. Antirheumatic agents in covid-19: is IL-6 the right target?
32369612 2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma
32278585 2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
32352361 2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists
32253759 2020. Tocilizumab treatment in COVID-19: A single center experience
32171193 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
32209313 2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
32369191 2020. Tocilizumab for the treatment of severe coronavirus disease 2019
32297987 2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection
32358817 2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome
32282956 2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab
C7187784 ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab
32350134 2020. Effective treatment of severe COVID-19 patients with tocilizumab
32365207 ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
32376396 2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32380318 2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32402416 ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides ...
| 32321563 2020. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome |
32389721 ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32387320 ä. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
